Consistent with previous findings in glioblastoma13, a functional inhibition screen in two Group 3 MYC-amplified medulloblastoma cell lines shows that co-amplified enhancer function differs depending on the architecture of the amplification. The gene discussed is MYC; the disease is medulloblastoma.